检索结果-南通市图书馆

Inhibition of elastin and collagen networks degradation in human skin by gingival fibroblast. In vitro, ex vivo and in vivo studies.

引用

Journal of Cosmetics, Dermatological Sciences and Applications 2011年第1期1卷 4-14页

作者： Bruno Gogly Francois Come Ferré Hafida Cherifi Adrien Naveau benjamin Philippe fournier 不详

Skin aging shows an imbalance between synthesis and degradation of the extracellular matrix. The overproduction of degradative enzymes (MMPs) during the chronology- and photo-induced aging leads to a degradation of the elastic and collagen networks. In a model of collagen and elastin destruction, we showed that the gingival fibroblast was able to preserve these macromolecules by inhibiting the overproduction of metalloproteinases by overproduction of TIMP-1 and modulation of the inflammatory cytokines activity. The objective of this study is to evaluate the effect of the gingival fibroblasts on human skin. The results in vitro and ex vivo show that the gingival fibroblast protects the skin collagen and elastic network by the inhibition of MMPs which leads to an overproduction of the TIMP-1. Moreover, the gingival fibroblast modulates the activity of some enzymes responsible for the inflammation;they inhibit the IL-1β and stimulate the production of TGF-β1. In vivo studies with a duration of six months and 50 women with pronounced wrinkles show that the culture supernatant of gingival fibroblasts diluted to 5% leads to a statistically significant decrease in the number and length of wrinkles.

关键词： elastin collagen skin Matrix Metalloproteinases gingival fibroblast

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Oral Manifestations of Neurofibromatosis Type 1

引用

Journal of Cosmetics, Dermatological Sciences and Applications 2019年第1期9卷 41-55页

作者： Hafida Cherifi benjamin fournier Ariane Berdal Blake McAlpin Ishai-Yaacov Sitbon Bruno Gogly Henri Mondor Hospital Dental DepartmentParis Descartes UniversityParisFrance Laboratory of Molecular Oral Pathophysiology ParisFrance Rotschild Hospital Centre de reference MAFACEParis Diderot UniversityParisFrance Neuroimmunology Laboratory Department of Symptom ResearchDivision of Internal MedicineUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Neurofibromatosis type 1 (NF-1) is a common genetic disorder with a highly variable phenotype. The disease affects both proliferation and differentiation of cells of neurectodermal origin. The presence of tumors is very common like benign nodular neurofibromas. Tumors with unclear prognosis may be present like plexiform neurofibromas whose prognosis is more uncertain. While many organs exhibit pathologies, most commonly affected are the nervous system, skin, gastrointestinal tract and heart. Oral abnormalities are also very common: 72% of NF-1 patients exhibit pathologies in oral mucosa, gums, maxillary and temporomandibular joints, and teeth. The incidence of NF-1 and its relationship to the prevalence of caries have been discussed in other researches. It is known that poor oral hygiene plays a key role in the development of periodontal disease and caries. Here we review the oral manifestations of neurofibromatosis type 1 that we illustrate by a patient followed in the center of rare diseases of the hospital Henri Mondor, clinical service in which we work.

关键词： Neurofibromatosis Type 1 Genetic Disorder Oral Tumor Jaw Abnormalities Periodontal Disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and tolerability of chitin-glucan combined with simethicone(GASTRAP^(■)DIRECT)in irritable bowel syndrome:A prospective,open-label,multicenter study

引用

World Journal of Gastrointestinal Pharmacology and Therapeutics 2024年第3期15卷 10-22页

作者： Nathalie Talbodec Pauline Le Roy Peggy fournier Benoit Lesage Elodie Lepoutre François Castex Jean Michel Godchaux Lionel Vandeville benjamin Bismuth Xavier Lesage Pauline Bayart Michael Genin Christel Rousseaux Veronique Maquet Salvatore Modica Pierre Desreumaux Caroline Valibouze Department of Gastroenterology Hôpital privéLe BoisLille 59000France Department of Gastroenterology Hôpital privéde Villeneuve d’AscqVilleneuve d’Ascq 59650France Univ.Lille CHU LilleULR 2694–METRICSÉvaluation des Technologies de Santéet des Pratiques MédicalesLille 59000France Development of Intestinal Biotech 1 Avenue Oscar LambretLille 59045France KitoZyme SA Parc Industriel des hauts Sarts Zone 2Rue de MilmortHerstal 4040Belgium BiOkuris A Parc Industriel des hauts Sarts Zone 2Rue de MilmortHerstal 4040Belgium Department of Hepato-Gastroenterology Lille University HospitalLille 59000France U1286-INFINITE Institute for Translational Research in InflammationUniv.LilleInsermCHU LilleLille 59000France Department of Digestive Surgery and Transplantation Lille University HospitalLille 59037France

BACKGROUND Irritable bowel syndrome(IBS),defined according to the Rome IV diagnostic criteria,is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain related to altered bowel ***-line recommended treatments are limited to combining drugs targeting predominant symptoms,particularly pain(antispasmodics),constipation(laxatives),and diarrhea(loperamide),yielding only a limited therapeutic ***^(■)DIRECT is a class IIa medical formulation composed of a combination of chitin-glucan and simethicone indicated for the symptomatic treatment of gas-related gastrointestinal disorders by combining different mechanisms of *** To evaluate the efficacy,tolerability,and safety of 4-week GASTRAP^(■)DIRECT treatment in patients with *** In this prospective,multicenter,open-label trial,120 patients with IBS received three sticks of GASTRAP^(■)DIRECT(1.5 g/d of chitin-glucan and 0.75 mg/d of simethicone)per day for 4 *** primary endpoint was the responder rate,defined as the number of patients whose abdominal pain score decreased by≥30%from baseline to week(W)*** analysis was performed using the per-protocol *** symptoms,impact of global symptoms on daily life,change in stool consistency,and improvement in defecatory disorders were *** Overall,100 patients were *** W4,67%(95%CI:57-75)showed improvement in abdominal pain(score:5.8±2.4 vs 2.9±2.0,P<0.0001).Similar improvements were observed for bloating[8.0±1.7 vs 4.7±2.9,P<0.0001;60%(95%CI:50-70)responders],abdominal distension[7.2±2.1 vs 4.4±3.1,P<0.0001;53%(95%CI:43-63)responders],and impact of global symptoms on daily life[7.1±2.0 vs 4.6±2.9,P<0.0001;54%(95%CI:44-64)responders].Stool consistency improved in most patients(90%and 57%for patients with liquid and hard stools,respectively).Overall,42%of patients with defecatory disorders reported very much/considerable improvements by *** severe adverse event occurred,and tolerabil

关键词： Chitin-glucan Irritable bowel syndrome Abdominal pain Flatulence Defecatory disorders Stool consistency Natural non-pharmacological treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：